Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 5 | 5 |
| List of Tables | 8 | 1 |
| List of Figures | 9 | 1 |
| Biological Strategies in the Emerging Markets - Introduction | 10 | 7 |
| Emergence of New National Markets | 10 | 1 |
| Shift in Emphasis Towards Biologicals | 10 | 1 |
| Obsolescence of Blockbusters | 10 | 1 |
| What Defines a Biological Product? | 10 | 1 |
| Why do Companies Want to Introduce Biologicals in BRIC Markets? | 10 | 1 |
| What Biological Products are Currently Available and in What Therapy Areas? | 11 | 1 |
| Monoclonal Antibodies | 11 | 1 |
| Anti-cancer mAbs | 12 | 1 |
| Anti-TNF | 12 | 1 |
| Therapeutic Proteins | 12 | 1 |
| Insulin | 13 | 1 |
| Erythropoietin | 13 | 1 |
| Growth Hormone | 13 | 1 |
| Cytokines | 13 | 1 |
| Blood Factors | 14 | 1 |
| Market Status of Therapeutic Proteins | 15 | 1 |
| Vaccines | 16 | 1 |
| What are the Most Attractive Emerging Markets for Biologicals? | 16 | 1 |
| Market Size | 16 | 1 |
| Price Considerations | 16 | 1 |
| Government Attitudes | 16 | 1 |
| Biological Strategies in the Emerging Markets - Market Characterization and Forecasts | 17 | 13 |
| Market Size in BRIC Countries | 17 | 1 |
| Brazil | 17 | 1 |
| Health and Healthcare | 17 | 1 |
| Pharmaceutical Market and Forecasts | 18 | 1 |
| M&A Activity | 18 | 1 |
| Russia | 19 | 1 |
| Health and Healthcare | 19 | 1 |
| Pharmaceutical Market and Forecasts | 20 | 1 |
| Foreign Investment | 20 | 1 |
| India | 21 | 1 |
| Health and Healthcare | 21 | 1 |
| Indian Pharmaceutical Market | 21 | 1 |
| China | 22 | 1 |
| Health and Healthcare | 22 | 1 |
| Pharmaceutical Market and Forecasts | 23 | 1 |
| Domestic Market | 24 | 1 |
| Healthcare Reform | 24 | 1 |
| Foreign Investment | 25 | 1 |
| Market Size in Second-tier Emerging Markets | 26 | 1 |
| Mexico | 26 | 1 |
| Turkey | 26 | 1 |
| South Korea | 26 | 1 |
| South Africa | 27 | 1 |
| Other Emerging Markets | 27 | 1 |
| BRIC Market Forecasts | 27 | 2 |
| Conclusions | 29 | 1 |
| Biological Strategies in the Emerging Markets - Market Drivers And Restraints | 30 | 12 |
| Summary of National Markets | 30 | 1 |
| Brazil | 30 | 1 |
| Russia | 30 | 1 |
| India | 30 | 1 |
| China | 30 | 1 |
| Meeting Clinical Needs | 31 | 1 |
| Government Controls - Price and Product Access | 32 | 1 |
| Brazil | 32 | 1 |
| Russia | 32 | 1 |
| India | 33 | 1 |
| China | 33 | 1 |
| PESTLE Analyses | 34 | 1 |
| Brazil | 34 | 2 |
| Russia | 36 | 1 |
| India | 37 | 2 |
| China | 39 | 2 |
| Overall Conclusions | 41 | 1 |
| Biological Strategies in the Emerging Markets - Regulatory Landscape | 42 | 8 |
| Overview of Regulatory Environment in the BRIC countries | 42 | 1 |
| Brazil | 42 | 1 |
| Russia | 43 | 1 |
| India | 44 | 1 |
| China | 45 | 1 |
| Regulations in Other Emerging Markets | 46 | 1 |
| Turkey | 46 | 1 |
| South Korea | 46 | 1 |
| Intellectual Property in BRIC Markets | 46 | 1 |
| Brazil | 46 | 1 |
| Russia | 47 | 1 |
| India | 47 | 1 |
| China | 48 | 1 |
| Future of IP in BRIC Markets | 48 | 1 |
| Patents | 48 | 1 |
| Conclusions | 49 | 1 |
| Biological Strategies in the Emerging Markets - Trend Analysis | 50 | 6 |
| Demographic and Disease Trends | 50 | 1 |
| Aging Populations | 50 | 1 |
| Unmet Clinical Needs | 50 | 1 |
| Immune Openings for Biologics | 50 | 1 |
| Growing Incidence of Cancer | 50 | 1 |
| R&D Challenges and Changes | 51 | 1 |
| M&As Build Pipelines and Profitability | 51 | 1 |
| Pricing Trends | 51 | 2 |
| Flexibility | 53 | 1 |
| Regulatory Trends | 53 | 1 |
| National Market Trends | 54 | 1 |
| Conclusions | 55 | 1 |
| Biological Strategies in the Emerging Markets - Pipeline Analysis | 56 | 11 |
| Introduction | 56 | 2 |
| Cancer | 58 | 1 |
| Cancer mAbs | 59 | 2 |
| Cancer - Therapeutic Proteins | 61 | 1 |
| Diabetes | 62 | 1 |
| Hormone Therapies | 63 | 1 |
| Hemopoietic Therapies | 64 | 1 |
| Immune Disease | 64 | 2 |
| Overall Conclusions | 66 | 1 |
| Biological Strategies in the Emerging Markets - Company Analysis | 67 | 15 |
| Introduction | 67 | 1 |
| Hoffman-La Roche | 68 | 1 |
| Biologics | 68 | 1 |
| Presence in BRIC Markets | 68 | 1 |
| Brazil | 68 | 1 |
| Russia | 68 | 1 |
| India | 69 | 1 |
| China | 69 | 1 |
| Novo Nordisk | 70 | 1 |
| Biologics | 70 | 1 |
| Presence in BRIC Markets | 70 | 1 |
| Brazil | 70 | 1 |
| Russia | 70 | 1 |
| India | 71 | 1 |
| China | 71 | 1 |
| Johnson &Johnson | 71 | 1 |
| Biologics | 71 | 1 |
| Presence in BRIC Markets | 72 | 1 |
| Brazil | 72 | 1 |
| Russia | 72 | 1 |
| India | 73 | 1 |
| China | 73 | 1 |
| Sanofi | 73 | 1 |
| Biologics | 73 | 1 |
| Presence in BRIC Markets | 74 | 1 |
| Brazil | 74 | 1 |
| Russia | 74 | 1 |
| India | 75 | 1 |
| China | 75 | 1 |
| Eli Lilly | 76 | 1 |
| Biologics | 76 | 1 |
| Presence in BRIC Markets | 76 | 1 |
| Brazil | 76 | 1 |
| Russia | 76 | 1 |
| India | 77 | 1 |
| China | 77 | 1 |
| Sandoz | 78 | 1 |
| Biologics | 78 | 1 |
| Presence in BRIC Markets | 78 | 1 |
| Brazil | 78 | 1 |
| Russia | 78 | 1 |
| India | 79 | 1 |
| China | 79 | 1 |
| Teva | 79 | 1 |
| Biologics | 79 | 1 |
| Presence in BRIC Markets | 80 | 1 |
| Brazil | 80 | 1 |
| Russia | 80 | 1 |
| India | 80 | 1 |
| China | 80 | 1 |
| Conclusions | 81 | 1 |
| Biological Strategies in the Emerging Markets - Business Strategies | 82 | 10 |
| Launch Strategies | 82 | 1 |
| Timing of Launch | 82 | 1 |
| Innovative Drug Launch | 83 | 1 |
| Comprehensive Launch Plan | 83 | 1 |
| Pricing Strategy versus Affordability | 83 | 1 |
| Healthcare Access versus Uptake | 83 | 1 |
| No One Size Fits All Policy | 84 | 1 |
| Marketing Strategies | 84 | 1 |
| Brazil | 84 | 1 |
| Russia | 84 | 1 |
| India | 85 | 1 |
| China | 85 | 1 |
| Pricing Strategies | 86 | 1 |
| Brazil | 86 | 1 |
| Russia | 86 | 1 |
| India | 86 | 1 |
| China | 86 | 1 |
| Partnering Strategies | 87 | 1 |
| Brazil | 87 | 1 |
| Russia | 87 | 1 |
| India | 88 | 1 |
| China | 89 | 1 |
| Manufacturing Strategies | 89 | 1 |
| Competition | 89 | 1 |
| Outlook | 90 | 1 |
| Overall Conclusions | 91 | 1 |
| Biological Strategies in the Emerging Markets - Appendix | 92 | 6 |
| Key Definitions | 92 | 1 |
| Abbreviations (in alphabetical order) | 92 | 2 |
| Sources | 94 | 2 |
| Methodology | 96 | 1 |
| Primary Research | 96 | 1 |
| Secondary Research | 96 | 1 |
| Contacts Us | 96 | 1 |
| Disclaimer | 97 | 1 |